|

Pembrolizumab (KEYTRUDA(R)) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Gastrointestinal/Genitourinary Cancers1
  • Endocrine Tumors1
  • Neuroendocrine Tumors1
  • Ovarian Cancer1
  • Multiple Myeloma1

Bethesda, Maryland1 trial

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.